Immunogenic cell death inducers trigger release of HMGB1, which by binding to TLR4, promotes the processing and presentation of tumor antigens by inhibiting their premature lysosomal degradation (Apetoh et al., 2007a; Apetoh et al., 2007b). Here, HMGB1 is linked to neoplasm.